Company Overview and News

0
HBF scraps planned $4b merger with HCF

2018-06-01 abc.net.au
Western Australia's largest health insurer, HBF, has pulled out of a planned merger with eastern states not-for-profit health fund HCF.
MDBKY MPL

7
ASX closes lower as Westpac and Treasury Wine fall

2018-05-17 theage.com.au
Australian shares fell for the second session this week led lower by Westpac, CSL and Treasury Wine stocks.
MDBKY KDR MPL GXY GALXF CCLAY CCL MALRY CCLAF MALRF MIN

7
ASX closes lower as Westpac and Treasury Wine fall

2018-05-17 smh.com.au
Australian shares fell for the second session this week led lower by Westpac, CSL and Treasury Wine stocks.
MDBKY KDR MPL GXY GALXF CCLAY CCL MALRY CCLAF MALRF MIN

12
Case for gender diversity on boards will survive the post-AMP backlash

2018-05-12 theage.com.au
It was a sharply-worded question, read aloud almost two hours into the fractious and agonisingly drawn-out annual meeting of troubled wealth giant AMP.
MBL DSH FBU MGR MYGSF MYRSY FCREY MRVGF FRCEF OGFGY FSUGY MDBKY MYR MPL FSUMF FBU INCZY FMG OGFGF ICPVF IPL ORG

12
Case for gender diversity on boards will survive the post-AMP backlash

2018-05-12 smh.com.au
It was a sharply-worded question, read aloud almost two hours into the fractious and agonisingly drawn-out annual meeting of troubled wealth giant AMP.
MBL DSH FBU MGR MYGSF MYRSY FCREY MRVGF FRCEF OGFGY FSUGY MDBKY MYR MPL FSUMF FBU INCZY FMG OGFGF ICPVF IPL ORG

12
'The ship has sailed' - push back against on women on boards will fail

2018-05-11 theage.com.au
It was a sharply-worded question, read aloud almost two hours into the fractious and agonisingly drawn-out annual meeting of troubled wealth giant AMP.
MBL DSH FBU MGR MYGSF MYRSY FCREY MRVGF FRCEF OGFGY FSUGY MDBKY MYR MPL FSUMF FBU INCZY FMG OGFGF ICPVF IPL ORG

12
'The ship has sailed' - push back against on women on boards will fail

2018-05-11 smh.com.au
It was a sharply-worded question, read aloud almost two hours into the fractious and agonisingly drawn-out annual meeting of troubled wealth giant AMP.
MBL DSH FBU MGR MYGSF MYRSY FCREY MRVGF FRCEF OGFGY FSUGY MDBKY MYR MPL FSUMF FBU INCZY FMG OGFGF ICPVF IPL ORG

34
The man with one of the toughest jobs in Australian business

2018-04-30 theage.com.au
The man with one of the toughest jobs in Australian business – interim AMP executive chairman Mike Wilkins – established a reputation for integrity during a long career in the financial services industry.
MDBKY BRK.A MPL

34
The man with one of the toughest jobs in Australian business

2018-04-30 smh.com.au
The man with one of the toughest jobs in Australian business – interim AMP executive chairman Mike Wilkins – established a reputation for integrity during a long career in the financial services industry.
MDBKY BRK.A MPL

0
A celebrity planner's world comes crashing down over risible advice

2018-04-24 theage.com.au
High flying celebrity financial planner Sam Henderson's world came crashing down on Tuesday as the banking royal commission heard he instructed his employees to impersonate a client, misrepresented his tertiary qualifications, failed to disclose a conflict of interest and gave advice to one client that was described as "risible".
MDBKY MPL

0
A celebrity planner's world comes crashing down over risible advice

2018-04-24 smh.com.au
High flying celebrity financial planner Sam Henderson's world came crashing down on Tuesday as the banking royal commission heard he instructed his employees to impersonate a client, misrepresented his tertiary qualifications, failed to disclose a conflict of interest and gave advice to one client that was described as "risible".
MDBKY MPL

14
ASX finishes flat on banks

2018-04-17 theage.com.au
The Australian market ended flat on Tuesday, with the benchmark once again failing to stretch to a third consecutive session of gains.
OISHY SCEXF MS.PRE VLRSY MS.PRF MS.PRG VRL MS.PRA WHC VLRDF MDBKY OISHF MPL MS.PRI MS.PRK VLRDY MS SAR OSH

14
ASX finishes flat on banks

2018-04-17 smh.com.au
The Australian market ended flat on Tuesday, with the benchmark once again failing to stretch to a third consecutive session of gains.
OISHY SCEXF MS.PRE VLRSY MS.PRF MS.PRG VRL MS.PRA WHC VLRDF MDBKY OISHF MPL MS.PRI MS.PRK VLRDY MS SAR OSH

4
Australian shares seal worst March quarter since financial crisis

2018-03-29 theage.com.au
Australian shares on Thursday wrapped up their worst March quarter performance since the GFC on a suitably sour note despite a modest rebound in the major banks.
MDBKY MPL DB

4
Australian shares seal worst March quarter since financial crisis

2018-03-29 smh.com.au
Australian shares on Thursday wrapped up their worst March quarter performance since the GFC on a suitably sour note despite a modest rebound in the major banks.
MDBKY MPL DB

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to ASX:MPL / MEDIBANK PRIVATE LIMITED on message board site Silicon Investor.

President Barack Obamau0027s Complete List of Historic Firsts Gripes, compliments, fishing and weather
Sharps Compliance Corp. (SMED) Implant Sciences Corporation - DIAMOND IN THE ROUGH?
VSE Corp (VSEC)--turnaround is about complete California Amplifier - 2
Amplitech Group Inc. Stock Attack II - A Complete Analysis
San Marco (SMN.V) Samples 8.46 g/t Gold; 43.0 g/t Silver; 1. Complete Genomics GNOM DNA analysis for human genome